Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Other Non-Current Liabilities (2024 - 2025)

Caris Life Sciences has reported Other Non-Current Liabilities over the past 2 years, most recently at $42.4 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $42.4 million for Q4 2025, down 4.57% from a year ago — trailing twelve months through Dec 2025 was $42.4 million (down 4.57% YoY), and the annual figure for FY2025 was $42.4 million, down 4.57%.
  • Other Non-Current Liabilities for Q4 2025 was $42.4 million at Caris Life Sciences, down from $44.4 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for CAI hit a ceiling of $44.4 million in Q4 2024 and a floor of $42.4 million in Q4 2025.